VIKING THERAPEUTICS
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. The Company’s lead clinical program is VK0612, a first-in-class, orally available drug candidate type 2 diabetes. The Company’s second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia. Viking is also developing three novel preclinical programs targeted at metabolic diseases and anemia.
VIKING THERAPEUTICS
Industry:
Health Care Medical Therapeutics
Founded:
2012-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.vikingtherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(858) 550-7810
Email Addresses:
[email protected]
Total Funding:
1.06 B USD
Technology used in webpage:
Domain Not Resolving Google Maps HSTS IPv6 Cloudflare Hosting Cloudflare CDN Cloudflare Microsoft Cloudflare Bot Manager Cloudflare SSL
Similar Organizations
Aardvark Therapeutics
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Ardelyx
Ardelyx develops novel oral therapeutics to treat mineral metabolism and metabolic disorders.
Bone Health Technologies
Bone Health Technologies is developing a new standard of care for treating both osteoporosis and osteopenia, the precursor to osteoporosis.
Boulder Care
Boulder is a telehealth provider of treatment and long-term support for people with substance use disorders
C4 Therapeutics
C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Faeth Therapeutics
Faeth Therapeutics is a cancer metabolism company that focuses on nutrition treatments for cancer patients.
IVX Health
IVX Health is a provider of infusion and injection therapy for those with complex chronic conditions.
Kaia Health
Kaia Health is a digital therapeutics company that creates evidence-based treatments for a range of medical disorders.
SPR Therapeutics
SPR Therapeutics is a medical device company.
Current Employees Featured
Founder
Stock Details
Investors List
Aspire Capital Partners LLC
Aspire Capital Partners LLC investment in Post-IPO Equity - Viking Therapeutics
Ligand Pharmaceuticals
Ligand Pharmaceuticals investment in Debt Financing - Viking Therapeutics
Official Site Inspections
http://www.vikingtherapeutics.com Semrush global rank: 605.5 K Semrush visits lastest month: 53.15 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Viking Therapeutics"
Home - Viking Therapeutics
Novel therapeutics for metabolic and endocrine disorders.See details»
Viking Therapeutics - Viking Therapeutics
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine …See details»
Viking Therapeutics - Overview
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.See details»
Viking Therapeutics - Crunchbase Company Profile
Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Viking’s research and development activities leverage …See details»
Management - Viking Therapeutics
Prior to founding Viking Therapeutics, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, where he was responsible for coverage of small and mid …See details»
Viking Therapeutics InvestorRoom - Corporate Presentation
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.See details»
Viking Therapeutics, Inc. | LinkedIn
Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders.See details»
Viking Therapeutics Announces Positive Top-Line Results from …
Feb 27, 2024 · Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo. Up to 13.1% …See details»
Viking to charge quickly into phase 3 with obesity med …
Jul 25, 2024 · Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million.See details»
Viking Therapeutics - VentureRadar
Website: http://www.vikingtherapeutics.com/ Develops novel, orally available therapies for metabolic and endocrine disorders, leveraging expertise in metabolism to improve patients' …See details»
Board of Directors - Viking Therapeutics
Dr. Macartney has served as the Chairperson of our Board since May 2015 and as a member of our Board since May 2014. From January 2017 to June 2017, Dr. Macartney served as CEO …See details»
Viking Therapeutics notches success with weight-loss drug trial, …
Feb 27, 2024 · Viking Therapeutics said on Tuesday its experimental drug helped patients with obesity lose nearly 15% of their body weight on average in a mid-stage study, and its share …See details»
News & Events - Viking Therapeutics InvestorRoom
SAN DIEGO, Feb. 7, 2024 / PRNewswire / -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel …See details»
Viking Therapeutics Reports Second Quarter 2024 Financial …
Jul 24, 2024 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and …See details»
Viking Therapeutics to Report Financial Results for Second Quarter …
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and …See details»
Viking Therapeutics Reports Third Quarter 2024 Financial Results …
SAN DIEGO, Oct. 23, 2024 / PRNewswire / -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel …See details»
Pipeline Overview - Viking Therapeutics
Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives.See details»
Viking Therapeutics - Press Releases
Nov 12, 2024 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and …See details»
VK2809 - Viking Therapeutics
Our lead clinical program’s drug candidate, VK2809, is a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for liver tissue, as well as the beta …See details»
Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial …
Jun 24, 2021 · VK0214 is a novel, orally available small molecule TRβ agonist that recently completed a successful Phase 1 single ascending dose (SAD) and multiple ascending dose …See details»